The American Journal of Managed Care

After a Year, ITCA 650 Produces Lower A1C, More Weight Loss Than Sitagliptin

Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel ...
CNBC

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

HAYWARD, Calif., Oct. 3, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced the presentation of an analysis of phase 2 clinical study results for ITCA 650 (continuous subcutaneous delivery of ...
The American Journal of Managed Care

ITCA 650 Results Point to "Transformational" Method to Deal With Poor Adherence in Type 2 Diabetes

In a packed session at the 75th Scientific Sessions of the American Diabetes Association, the lead investigator told attendees how a matchstick-size device delivered exenatide, producing lower blood ...
FierceBiotech

Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

BOSTON, Oct. 1, 2014 -- Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide, delivered continuously once or ...